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Background: Cerebral cavernous malformations (CCMs) are common vascular
malformations that predominantly arise in the central nervous system and are mainly
characterized by enlarged vascular cavities without intervening brain parenchyma.
Familial CCMs (FCCMs) is inherited in an autosomal dominant pattern with incomplete
penetrance and variable symptoms.
Methods: Mutations of three pathogenic genes, CCM1, CCM2, and CCM3, were
investigated by direct DNA sequencing in a Chinese family with multiple CCM lesions.
Results: Four heterozygous variants in the CCM2 gene, including one deletion
(c.95delC), a missense mutation (c.358G>A, p.V120I), one silent mutation (c.915G>A,
p.T305T), and a substitution (c. ∗1452 T>C), were identified in the subjects with multiple
CCM lesions, but not in a healthy sibling. Among these variants, the c.95delC deletion is a
novel mutation which is expected to cause a premature termination codon. It is predicted
to produce a truncated CCM2 protein lacking the PTB and C-terminal domains, thus
disrupting the molecular functions of CCM2.
Conclusions: The novel truncating mutation in the CCM2 gene, c.95delC, may be
responsible for multiple CCM lesions in a part of FCCM. In addition, it may represent a
potential genetic biomarker for early diagnosis of FCCM.
Keywords: familial cerebral cavernous malformations (FCCM), susceptibility-weighted imaging (SWI), CCM2,
mutation, pathogenesis, biomarker
INTRODUCTION
Cerebral cavernous malformations (CCMs) are common vascular defects with a prevalence of
1 in every 200–250 individuals. They mostly occur in the central nervous system (e.g., the
forebrain, brainstem, cerebellum, spinal cord, cranial nerves, and cerebral ventricles, Gomori et al.,
1986; Rigamonti et al., 1987). Histologically, CCMs are characterized by abnormally enlarged
capillary-like vascular channels lined by a single layer of endothelium without intervening brain
parenchyma (Gomori et al., 1986; Rigamonti et al., 1987). As one of the most common types
of vascular malformations found in the brain, CCMs represent up to 15% of all CNS vascular
malformations (Cavalcanti et al., 2012). They affect up to 0.5% of the global population, accounting
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for approximately 24 million people worldwide (Rigamonti
et al., 1988; Otten et al., 1989; Cavalcanti et al., 2012), and
their observed prevalence will increase with the widespread
application of magnetic resonance imaging (MRI), and especially
susceptibility-weighted imaging (SWI), in clinical diagnosis (de
Souza et al., 2008).
Clinical symptoms of CCMs usually appear between 20 and
50 years of age (with an average age of onset of approximately
30 years), but they can also arise in early infancy or old
age (Labauge et al., 2007; Cavalcanti et al., 2012). The most
common manifestations include seizures, recurrent headaches,
hemorrhagic stroke, epileptic attacks, and focal neurological
deficits, but some CCMs can also be relatively asymptomatic
(Labauge et al., 1998, 2007). The percentage of CCMs patients
who remain symptom-free throughout their lives has been
estimated to be as high as 40% (Labauge et al., 2007; Mondejar
et al., 2014).
CCMs can present as either a sporadic form, usually with
a single lesion, or familial form, mostly with multiple lesions
(Rigamonti et al., 1988). The proportion of Familial CCMs
(FCCM) has been estimated to be as high as 50% in Hispanic-
American patients and close to 10–40% in Caucasian patients
(Rigamonti et al., 1988; Labauge et al., 2007). The prevalence
of FCCM has not been investigated in the Chinese population.
FCCM are inherited in an autosomal dominant fashion with
incomplete penetrance and variable expressivity (Bicknell et al.,
1978). To date, three causative genes have been identified
in the etiology of FCCM (Cavalcanti et al., 2012). They are
CCM1 (KRIT1), CCM2, and CCM3 (PDCD10), which encode
the proteins krev/rap1 interacting trapped 1 (Krit1), malcavernin,
and programmed cell death 10 (PDCD10), respectively (Labauge
et al., 2007; Cavalcanti et al., 2012). These three proteins
form a heterotrimeric complex that is critical for different
molecular pathways, including angiogenesis and normal vascular
morphogenesis in the brain (Zawistowski et al., 2005; Voss et al.,
2007; Pagenstecher et al., 2009; Faurobert and Albiges-Rizo, 2010;
Li et al., 2010; Stockton et al., 2010; Cavalcanti et al., 2012). The
loss of these functions of CCM proteins resulting frommutations
in CCMgenes leads to CCMs (Stahl et al., 2008; Chan et al., 2011).
Here, we report the clinical and neuroradiological features of a
Chinese family with multiple CCMs, along with a genetic analysis
of the CCM1/CCM2/CCM3 genes in three family members
through a genomic DNA-targeted sequencing method. We
identify four mutations in CCM2, among which one mutation
(c.95 delC) in CCM2 is novel and may contribute to the
pathogenesis of a part of FCCM.
SUBJECTS AND METHODS
Subjects
A 57-year-old male patient (Figure 1 II-1), the proband, arrived
at the department of neurology, the First Affiliated Hospital of
Xiamen University, Xiamen, Fujian, China, showing symptoms
Abbreviations: FCCM, familial cerebral cavernous malformations; LOF, loss-of-
function; MRI, magnetic resonance imaging; PTB, phosphotyrosine-binding; SNP,
single nucleotide polymorphisms; SWI, susceptibility-weighted imaging.
of diplopia and hemidysesthesia only on the left. He denied
any fever, headache, vomiting, vertigo, hypertension, or trauma
as well as any other prior history (especially disorders in
central nervous system). A physical exam revealed paralysis
of the sixth nerve on the right side, but the other cranial
nerves appeared normal. No other neurological sign was
observed during his presentation and clinical observation.
His hematological and biochemical data from blood and
cerebrospinal fluid tests were normal. Serological tests for various
agents, including parasite antibodies were all negative. Non-
contrast computed tomography revealed multiple high-intensity
patchy calcifications or bleeding distributed around the cortical
and subcortical regions of the cerebral hemispheres, cerebellum
and brain stem (Figure 2A). Surprisingly, many additional
thick CCMs distributed throughout the brain (including the
cerebrum, cerebellum, thalamus, and brain stem) were detected
in susceptibility-weighted images (SWIs, Figure 2D). However,
they could not be detected by T1 or T2-weighted gradient
echo (GRE) sequences (Figures 2B,C). The diameters of the
lesions ranged from 0.5mm to 3 cm, averaging 0.9 cm. The
patient’s elder brother (Figure 1 II-2, aged 63 years) and younger
sister (Figure 1 II-3, aged 53 years) were asymptomatic. Both
siblings also denied trauma, prior history, or other special
medication history. They were also informed that they should
receive SWI scans. Although the proband’s elder brother (II-
2) did not presented much more and severer CCM lesions on
the cerebellum, cerebrum, thalamus, and brain stem than the
proband, he also showed a similar phenomenon, with multiple
CCM lesions in sections of the sellar region and parietal lobe
upon sagittal and coronal SWI imaging of the brain (Figure 2E).
The proband’s sister (II-3) did not show any CCMs in the SWI
scan of the brain (Figure 2F). The proband’s parents died several
years ago. Therefore, their MRI data were not available. Whole
blood samples were obtained from patient II-1 and his siblings,
subjects II-2 and II-3. This study was approved by the ethics
committee of Xiamen University. All study subjects provided
written informed consent.
Genetic Analysis
Genomic DNA was extracted from whole blood of the subjects
using the MagCore Genomic DNA Whole Blood Kit. All
of the coding exons of the CCM1 (GenBank: NG_012964.1,
including 20 exons), CCM2 (GenBank: NG_016295.1, including
10 exons), and CCM3 (GenBank: NG_008158.1, including 9
exons) genes were PCR amplified using a specific subset of primer
pairs (Supplemental Table 1). Then, the purified PCR products
were directly sequenced with a 3730 automatic sequencer
(Applied Biosystems, USA). The DNA sequences were analyzed
by the Sequencing Analysis Version 5.2 software package
(Applied Biosystems). Sequence alignment was performed with
DNAMAN software. The detected variants were described
according to the recommendations of the Human Genome
Variation Society, taking the A of the ATG translation initiation
codon as +1 at the cDNA level. The variants were considered
novel when they were not reported in previous publications
or in the following public databases: (1) CCM mutation
database (http://www.angiomaalliance.org/pages.aspx?content=
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FIGURE 1 | Pedigree of the studied Chinese family. The proband is
indicated by the arrow. Squares represent males; circles represent females.
Black-filled symbols indicate a member showing multiple cerebral cavernous
malformations upon SWI-MRI of the brain. A diagonal line through the symbol
represents a deceased person.
345&id=289); (2) National Center for Biotechnology Information
(NCBI) dbSNP (http://www.ncbi.nlm.nih.gov/snp/); (3) Exome
Variant Server for Exome Sequencing Project from the National
Heart, Lung, and Blood Institute (http://evs.gs.washington.
edu/EVS/); and (4) The Human Gene Mutation Database
(HGMD) (http://www.hgmd.org/). The effects of these variants
were evaluated with several types of predictive software,
including (1) MutationTaster (http://www.mutationtaster.org/);
(2) Mutalyzer (https://mutalyzer.nl/); (3) SplicePort (http://
spliceport.cbcb.umd.edu), (4) Alternative Splice Site Predictor
(ASSP) (http://wangcomputing.com/assp/index.html), and (5)
Human Splicing Finder (http://www.umd.be/HSF/). Finally, the
variants associated with the pathogenesis of FCCM were further
examined in 200 unrelated ethnically matched normal controls.
RESULTS
Targeted sequencing of the coding exons and intronic boundaries
of three CCM family genes revealed 4 variants in the CCM2
gene in both the proband (II-1) and his brother (II-2), but not
in his healthy sister (II-3). No variants were identified in the
CCM1 or CCM3 genes in any of the siblings. The CCM2 variant
2, NM_031443.3, is selected as the reference sequence of those
variants (Stahl et al., 2008). The four identified variants were
heterozygous in both siblings and are summarized in Table 1,
including one deletion in (c.95delC) exon 2, a missense mutation
(c.358G>A, NP_113631.1: p.V120I) in exon 4, one silent
mutation (c.915G>A, NP_113631.1: p.T305T) in exon 8, and a
substitution (c.∗1452 T>C) in exon 10 (Figure 3A). Among these
variants, only the c.95delC deletion was a novel mutation that
had not been reported in the NCBI dbSNP, HGMD, and CCM
mutation databases or the previous literature. Moreover, direct
sequence analysis of 200 healthy controls confirmed that it was
not a polymorphism but a mutation. Additionally, pathogenicity
analysis revealed that the novel deletion (c.95delC) in the CCM2
gene was a frameshift mutation, which could result in premature
termination at the 35th codon and cause a major truncation
corresponding to the last 409 amino acids at the C-terminus
of the full CCM2 protein (Figure 3B). Additionally, together
with MutationTaster and SplicePort, HSF predicted that this
mutation might disrupt the splice site and lead to a potential
splicing alteration. According to the applied in silico analysis
tools, three other variants were also predicted to alter donor splice
sites, probably affecting splicing. These variants were considered
as three single nucleotide polymorphisms (SNPs), rs11552377
(c.358G>A), rs2289367 (c.915G>A), and rs7804 (c.∗1452 T>C),
which could be found in the NCBI dbSNP database. They
appeared to occur in European, European American, African
American, and Asian Chinese populations. Among the variants
identified in the family examined in the present study, the c.∗1452
T>C (rs7804) substitution was the only mutation located in
the 3′ UTR region (Figure 3A). miRNA binding site prediction
analysis did not indicate that its neighboring region might act
as a potential miRNA binding site, suggesting that the c.∗1452
T>C variant could not contribute to the pathogenesis of FCCM
through the regulation of CCM2mRNA expression.
DISCUSSION
Familial cerebral cavernous malformations (FCCM), which
are commonly characterized by the presence of multiple
lesions upon cerebral computed tomography/MR imaging, are
a rare autosomal-dominant inherited disorder with incomplete
penetrance and wide phenotypic variability (Bicknell et al., 1978;
Labauge et al., 2007). FCCM are more likely to grow and form
new lesions and to present hemorrhages and neurological signs
than sporadic CCMs (Clatterbuck et al., 2000; Maiuri et al.,
2006; Labauge et al., 2007). Therefore, the identification of a
symptomatic proband with multiple CCM lesions prompted us
to perform both presymptomatic MRI screening and genetic
testing in the asymptomatic relatives to clarify this potential case
of familial CCMs. In the present study, we did not find any
mutations in CCM genes in the asymptomatic sibling without
CCM lesions, but we did identify four variants in the CCM2 gene
in two siblings with multiple CCM lesions, including one novel
frameshift mutation and three known polymorphisms. These
findings therefore confirmed this proband as a familial CCMs
case, rather than a sporadic CCMs case.
The pathogenesis of FCCM is mainly attributed to defects in
the CCM1, CCM2, and CCM3 genes (Stahl et al., 2008; Cavalcanti
et al., 2012; Draheim et al., 2014). More than 200 distinct
germline mutations in those three genes have been reported to
date (Cavalcanti et al., 2012; Zhu et al., 2014); however, they
account for only 70–80% of all FCCM cases (Denier et al.,
2006; Cavalcanti et al., 2012). Here, the CCM2 gene mutations
identified in two siblings may account for the etiology of a part of
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FIGURE 2 | CCM lesions diagnosed through CT, GE-and SWI-MRI. (A) CT of the 57-year-old proband, II-1. A plain CT scan (brain window images) showed
multiple calcification spots scattered on the tegmentum of the pons, temporal lobes and periventricular area. (B) Axial T1-weighted gradient-echo (GE) MR imaging of
the proband, II-1. Axial T1-weighted GE images demonstrated hyper-intensity of hemorrhage lesions. (C) Axial T2-weighted gradient-echo (GE) MR imaging of the
proband, II-1. T2-weighted GE images showed a “popcorn” appearance surrounded by a dark rim of hemosiderin. (D) SWI-MR imaging of the proband, II-1. SWI
(Continued)
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FIGURE 2 | Continued
revealed thickly dotted CCMs distributed throughout the cerebral cortex in the brain of the proband. There are dozens of lesions on the cerebrum, cerebellum,
thalamus, and brain stem. The diameter of the lesions ranges from a few millimeters to several centimeters. (E) SWI-MR imaging of the proband’s elder brother, II-2.
II-2 showed a similar phenomenon, with multiple CCM lesions observed upon SWI-MRI of the brain. (F) SWI-MR imaging of the proband’s younger sister, II-3. II-3 did
not show any CCM lesions upon SWI-MRI of the brain.
TABLE 1 | Mutations identified in siblings with CCMs (II-1 and II-2).
Region Nucleotide change (cDNA) Amino acid change Function Domain Mutation Type
CCM2 Exon 2 c.95 del C p. A32A Delection, Frameshift N-terminal domain Novel Heterozygous
CCM2 Exon 4 c.358 G>A p. V120I Missense PTB domain Known (rs11552377) Heterozygous
CCM2 Exon 8 c.915 G>A p. T305T Silent C-terminal Karet domain Known (rs2289367) Heterozygous
CCM2 3′UTR (Exon 10) c.*1452 T>C Null Unknown Null Known rs7804) Heterozygous
Genbank accession NM_031443.3 (CCM2 variant 2). The first nucleotide of ATG translation codon is considered nt +1. PTB, Phosphotyrosine-binding domain.
FCCM cases in China. CCM2 encodes a 444-amino acid protein,
also known as malcavernin, that contains a phosphotyrosine-
binding (PTB) domain (encoded approximately by residues from
60 to 220) at its N-terminus and a harmonin homology domain
(HHD) (encoded by residues approximately from amino acids
220 to 444) at its C-terminus (Fisher et al., 2013, 2015). It has
been shown that CCM2 can bind to CCM1 (Krit1) and CCM3
(PDCD10) through its PTB domain, thereby regulating cell-cell
junctions, cell-extracellular matrix adhesion and the proliferation
and migration of cells (Zawistowski et al., 2005; Zhang et al.,
2007; Faurobert and Albiges-Rizo, 2010; Li et al., 2010; Gingras
et al., 2012). CCM2 has also been found to act as scaffold
for the actin cytoskeleton machinery through simultaneously
binding Rac1 and MEKK3 in the p38 MAPK pathway to regulate
cytoskeleton reorganization (Uhlik et al., 2003; Zawistowski et al.,
2005). Additionally, Liraz Harel et al. have shown that CCM2
interacts with TrkA via its PTB domain and mediates TrkA-
induced cell death through its Karet domain in neuroblastoma
or medulloblastoma (Harel et al., 2009). These findings indicate
the crucial roles of CCM2 in the pathogenesis of vascular defects
in FCCM.
The c.95 delC mutation identified in the present study was
expected to generate a stop codon leading to the predicted
formation of a 35-amino acid truncated protein lacking the
original domains. This truncating mutation may disrupt all of
the functions of CCM2 in the maintenance of vascular integrity
and remodeling, thus triggering the onset of lesions. Why did the
two siblings with multiple CCM lesions not show severe clinical
symptoms, such as seizures and hemorrhage? The reason may
be that they were heterozygous for both mutations and retained
a portion of CCM function. Our hypothesis is supported by
a study that has revealed that loss-of-function (LOF) mutation
in CCM2, c.95 delC, cause endothelial cell dysfunction and
loss of vascular integrity in animal models (Boulday et al.,
2009; Chan et al., 2011). In line with our findings, previous
studies in many of FCCM cases have identified more than
40 LOF mutations within the CCM2 gene, which were either
missense mutations or frameshift deletions, that destroyed the
scaffold function of the protein or directly generated a truncated
protein without any functional domains (Liquori et al., 2003;
Stahl et al., 2008; Mondejar et al., 2014). These results indicate
that LOF mutations of CCM2 could be an important cause of
FCCM.
Bioinformatic analysis showed that the c.915G>A
substitution in the Karet domain and c.∗1452 T>C substitution
in the 3′UTR occurred within splicing sites, as observed for the
above variant, c.95delC. Although neither mutation altered the
amino acid sequence of CCM2 or potential miRNA binding sites,
they may contribute to the pathogenesis of FCCM by altering
splicing. Because RNA analysis has not been performed in this
present study, it will be necessary to evaluate the effect of putative
splicing mutations on the expression and function of CCM2 in
the future.
Furthermore, multiple alignment analysis revealed that as
same as the amino acids residues, 32Ala and 305Thr, 120Val that
is located in the PTB domain and is changed by the c.358G>A
variant is highly conserved amongmammal (Homo sapiens, Mus
musculus, Rattus norvegicus, Macaca mulatta, Bos taurus, Pan
troglodytes, Canis lupus familiaris, Sus scrofa). Compared with
rs2289367 (c.915G>A) and rs7804 (c.∗1452 T>C), the minor
allele frequency (MAF) of rs11552377 (c.358G>A) is relative
low, observed in 1000 Genomes (MAF = 0.1080) and ExAC
(MAF = 0.1461) databases. Additionally, the frequency of the
c.358G>A variant in Han-Chinese (MAF = 0.07) is much lower
than that in European (MAF = 0.18), but is a little higher
than that in African American (MAF = 0.03). The high MAF
of c.358G>A (rs11552377) in general population suggested it
as a benign polymorphism, rather a disease-causing mutation.
Together with Mutation Taster, both SIFT (Sorting Intolerant
From Tolerant) and Polyphen-2 (Polymorphism Phenotyping
v2) prediction of functional effects of c.358G>A (rs11552377)
further supported this opinion. Therefore, we think that the
novel truncating mutation, c.95delC, could be the driven factor
for multiple CCM lesions in the cases. The c.358G>A variant
changing the amino acid residue could not contribute to the
pathogenesis of FCCM through disrupting the structure of PTB
domain. Given that those variants were just identified in limited
cases in this study, we thought that it was necessary to verify them
in more FCCM cases, moreover confirm its significance in the
pathogenesis of FCCM.
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FIGURE 3 | Distribution and function of mutations in the CCM2 gene. (A) Schematic representation of four CCM2 gene mutations identified in the domains of
CCM2-coding protein in the studied Chinese family with FCCM. (B) A novel frameshift mutation in exon 2 of the CCM2 gene. This deletion (c.95 delC), located in
exon 2, was heterozygous in both siblings with CCMs. It resulted in a stop codon in the 36th original codon and produced a 35-amino acid, truncated form of CCM2,
without the PTB domain and all of the C-terminal domains.
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Confusingly, one of the proband’s siblings did not show
any manifestations but presented similar multiple CCM lesions
and a mutation pattern consistent with the affected proband.
The causes of this variability are unknown. We suggest that it
was likely associated with the incomplete clinical penetrance of
FCCM. The reason why the elder brother with multiple CCM
lesions showed asymptomatic may be the insufficiency of lesions
on several functional regions of the brain (e.g., cerebellum,
cerebrum, thalamus, and brain stem), especially on the junction
of the medulla oblongata and the pons that were related with
the diplopia and paralysis of those nerves. Additionally, other
genetic factors (such as the putative CCM4 gene), environmental
factors (causing different epigenetic regulation) or lifestyle could
also contribute to this difference in clinical penetrance between
these two siblings. Therefore, we think that CCM2 variants (e.g.,
the c. 95delC mutation) could be the driven factors for multiple
CCM lesions in both affected brothers. The different clinical
manifestations of two brothers are ascribed to the different
location and severity of CCM lesions, which may be the resulted
from individual differences in other unknown gene variants
or lifestyle associated epigenetics. To address such incomplete
clinical penetrance or phenotype variability among FCCM cases,
further studies are required to explore genotype-phenotype
correlations, particularly in relation to the nature of the mutated
gene in animal models.
CONCLUSION
In conclusion, we report a case of FCCM and its associated
symptoms and genotypes in a Chinese family. Among the four
identified variants in CCM2 gene, the c. 95delC mutation has
not been previously identified, either in China or elsewhere,
and it may represent a potential biomarker for FCCM cases.
Moreover, this novel mutation is expected to lead to a frameshift
mutation and produce a truncated form of CCM2 without the
PTB domain and all of the C-terminal domains, thus disrupting
the molecular functions of CCM2. Thus, it may contribute to the
pathogenesis of multiple CCM lesions in a part of FCCM cases.
We believe that it is necessary for clinicians and neuroscientists to
identify unaffected carriers of such mutations and asymptomatic
individuals with multiple CCM lesions in cases of FCCM as
early as possible, in addition to understanding the etiology of
FCCM through the use of neuroradiology screening and genetic
counseling.
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